Description
Indication & Scope
AiDaLuo® Ebdarokimab Injection treats adult patients with moderate to severe plaque psoriasis.
- Mechanism: Fully human monoclonal antibody targeting the shared p40 subunit of IL-12 and IL-23 cytokines. It blocks inflammatory cytokine receptor binding, suppresses abnormal Th1/Th17 immune activation and reduces skin inflammatory lesion formation.
- Drug class: IL-12/IL-23 dual-targeted monoclonal antibody, injectable autoimmune disease prescription biologic medicine.
- Clinical use: Long-term maintenance treatment for moderate-severe plaque psoriasis to improve skin lesions and quality of life.
| Generic Name | Ebdarokimab Injection |
| Brand Name | AiDaLuo |
| Ingredient | Ebdarokimab Injection |
| Dosage Form | Injection |
| Package | 135mg(1ml)*1 syringe/box |
| Conditions Treated | Moderate to severe plaque-type psoriasis |
| Taboos | Severe hypersensitivity to ebdarokimab or formulation excipients; patients with active severe systemic infection, active tuberculosis or untreated opportunistic infections |
| Place of origin | China |
| Prescription type | Prescription-only |
| Storage Conditions | Refrigerate at 2°C to 8°C, do not freeze, protect from direct sunlight |
| Manufacturer | KangFang Biopharmaceutical, Ltd. |
| Registration Authority | National Medical Products Administration (NMPA), China |
| Approval number | S20250017 |
| Approval Date | Apr 15, 2025 |
| Shelf Life | 24 months |
How to use ?
Recommended Dose: 135mg subcutaneous injection at Week 0 and Week 4, followed by 135mg maintenance dose once every 12 weeks thereafter.
Time: Fixed scheduled dosing throughout long-term treatment until clinical remission.
Instructions for use: Administer only via subcutaneous injection into the abdomen, rotate injection sites regularly, intravenous or intramuscular injection is prohibited.
Interaction: Concomitant use with other systemic immunosuppressants increases infection risk; live attenuated vaccines are not recommended during treatment.
Side effects: Upper respiratory tract infections, headache, injection site erythema and pain, fatigue, and rare hypersensitivity reactions.
Important Notice
This product should be administered only by qualified healthcare professionals in accordance with the approved prescribing information and local clinical guidelines. Dosage and administration may vary depending on patient condition, indicatiaon, and regional regulatory requirements.
Packaging & Shipping
Packaging
Original manufacturer’s packaging with secure export carton. Customized export packaging is available upon request.
Shipping Methods
Express Courier (EMS, DHL, FedEx, UPS), Air Freight, and Sea Freight. Cold-chain transportation is available for products requiring temperature-controlled logistics.
Export Support
Certificate of Analysis
GMP Certificate
Commercial Invoice
Packing List & CPP
Cold Chain Logistics
Customs Documentation
Scientific and regulatory sources
FAQ
What disease is Ebdarokimab Injection approved for?
It is indicated for the treatment of adult patients with moderate to severe plaque psoriasis.
What cytokines does Ebdarokimab Injection target?
It binds and inhibits the shared p40 subunit of IL-12 and IL-23 inflammatory cytokines.
What is the standard maintenance dosing interval of Ebdarokimab Injection?
After initial loading doses, the maintenance injection is given once every 12 weeks.
What are the common mild side effects of Ebdarokimab Injection?
Upper respiratory tract infection, headache, injection site redness and fatigue are frequent mild reactions.
AiDaLuo® | Ebdarokimab Injection | Plaque Psoriasis | DengYueRX
INN: Ebdarokimab Injection
Indications: Plaque psoriasis
Dosage Form: Injection
Strength: 135mg(1ml)/syringe
